Inactivated Whole Virus Influenza A (H5N1) Vaccine1 by Vajo, Zoltan et al.
LETTERS
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 5, May 2007  807    Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 5, May 2007  807 
Inactivated Whole 
Virus Inﬂ  uenza A 
(H5N1) Vaccine1
To the Editor: Avian inﬂ  uenza 
viruses of the H5N1 subtype represent 
a potential source of the next pandem-
ic (1,2). Our goal was to determine the 
safety and immunogenicity of a newly 
developed vaccine in humans.
The vaccine was produced by the 
same method as the interpandemic in-
ﬂ  uenza vaccine “FluvalAB” used in 
Hungary for the past 11 years (3,4). 
The method has been validated by 
meeting the requirements of the Eu-
ropean Agency for the Evaluation of 
Medicinal Products (EMEA) related 
to interpandemic inﬂ  uenza  vaccines 
each year since 1995, and by having 
been administered in humans in a total 
of >15 million cases (5).
The virus strain (NIBRG-14), 
a reverse genetics–derived 2:6 reas-
sortant between A/VietNam/1194/2004 
(H5N1) and PR8, was obtained from 
the National Institute for Biologic Stan-
dards and Control, London. It is one of 
the reference viruses indicated as suit-
able for use in a mock-up vaccine by 
the Committee for Medicinal Products 
for Human Use (6).
Hens’ egg–grown, formalde-
hyde-inactivated, whole virus vac-
cine, developed and produced by the 
Omninvest Ltd. (Budapest, Hungary), 
was used. The vaccine contained 6 
μg hemagglutinin per dose (as deter-
mined by single radial immundiffu-
sion test) in 0.5-mL ampules. Purity 
was assessed by endotoxin content 
(determined by chromogenic endo-
toxin assay, using a modiﬁ  ed limulus 
amoebocyte lysate and a synthetic 
color-producing substrate), which was 
considered acceptable in concentra-
tions <0.1 IU/mL. The amount of ov-
albumin was determined by ELISA, 
which was considered satisfactory in 
concentrations <10 ng/mL. Aluminum 
phosphate was used as adjuvant, in 
the amount of 0.31 mg Al per ampule; 
0.1 mg/mL merthiolate was added as       
preservative. 
A total of 146 healthy volunteers 
>18 years of age (mean ± SD 42.07 
± 12.62 years). were enrolled in the 
study. Sixty-ﬁ  ve male and 81 female 
volunteers participated. The sample 
size was chosen to exceed the require-
ment of 50 patients per group set by 
the European guidelines for yearly in-
ﬂ  uenza vaccine trials (5). The sponsor 
was the National Public Health and 
Medical Ofﬁ   cer Service, Budapest, 
Hungary.
The injection administered 0.5 
mL of vaccine intramuscularly. The 
injection was not repeated. Serum an-
tibody titers were measured by hem-
agglutination inhibition (HI) by us-
ing chicken erythrocytes, following 
standard procedures (7). Because the 
protective titer for inﬂ  uenza virus A 
(H5N1) infections is unknown, immu-
nogenicity was assessed according to 
the European Medicines Agency crite-
ria related to interpandemic inﬂ  uenza 
vaccines (Table) (5).
None of the study participants 
displayed measurable levels of HI an-
tibodies before vaccination. Accord-
ing to EMEA requirements, both male 
and female groups met 2 independent 
criteria for immunogenicity 21 and 90 
days after vaccination (Table).
In 15.7% of the participants, ad-
verse reactions in the form of local pain 
at the injection site occurred within 
the ﬁ  rst 48 hours; these reactions dis-
appeared within 1 day. No other local 
reactions, such as injection site indu-
ration, erythema, swelling, warmth, or 
ecchymosis, were noted. No systemic 
reaction (fever, malaise, headache, 
shivering) was detected. No serious 
adverse events were observed. These 
results are in line with the 11-year 
experience using the interpandemic 
vaccine produced by Omninvest Ltd. 
1The study design has been presented as 
an oral presentation at the World Health 
Organization Meeting on Evaluation 
of Pandemic Inﬂ   uenza Vaccines in 
Clinical Trials, May 4–5, 2006, Geneva, 
Switzerland.
Table. Immunogenicity findings of whole-virus influenza vaccine trial, Hungary*†   
CHMP
requirement
Total study 
population Male Female
Day 21 
 GMT  NA 27.9 31.0 25.6
  Post- to prevaccination GMT ratio (increase)  >2.5 5.6‡ 6.2‡ 5.1‡
  % of participants seropositive (titer >1:40)  >70 63.7‡ 70.8‡ 58.0
  % of participants with seroconversion (4-fold titer increase or titer >1:40)  >40 63.7* 70.8‡ 58‡
Day 90 
 GMT  NA 29.4 31.9 27.4
  Post- to prevaccination GMT ratio (increase)  >2.5 5.9‡ 6.4‡ 5.5‡
  % of participants seropositive (titer >1:40)  >70 67.3 73.9‡ 61.8
  % of participants with seroconversion (4-fold titer increase or titer >1:40)  >40 67.3‡ 73.9‡ 61.8‡
*CHMP, Committee for Medicinal Products for Human Use, European Medicines Agency; GMT, geometric mean titer; NA, not applicable.
†Hemagglutination-inhibition (HI) titers below the limit of detection were given an arbitrary value of 1:5. GMTs of antibody and their confidence intervals 
were computed by transforming the results to a logarithmic scale, assuming asymptotic normality conditions were satisfied on the scale and converting 
back to the original scale. HI endpoints were the GMT at each timepoint and the variables required for interpandemic influenza vaccines: postvaccination 
seropositivity rate (% of participants with titers  40), the post- to prevaccination GMT ratio, and the proportion of persons seroconverting or displaying a 4-
fold titer increase postvaccination. 
‡Met CHMP standards. LETTERS
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by the same method, where a similar 
safety proﬁ  le has been seen after >15 
million vaccinations in humans.
This is the ﬁ  rst study that reports 
that an inactivated whole virus vaccine 
with an aluminum phosphate adjuvant 
system against inﬂ  uenza  A  (H5N1) 
was safe and immunogenic in humans 
after only 1 injection. This study re-
ports the lowest effective dose used 
to cause immune response. Other tri-
als used much higher maximum doses 
and required 2 injections 21 or 28 days 
apart (8–10). Using the lowest possi-
ble amount of the antigen and fewer 
injections is essential for increasing 
the production capacity of vaccine 
manufacturers in a pandemic (2).
Using 1, instead of 2, injections 
will shorten the time needed to devel-
op immune response by 3–4 weeks. 
Unlike previous studies on inﬂ  uenza 
A (H5N1) vaccines that reported only 
data from 21, 28, or 56 days after the 
ﬁ   nal vaccination (8–10), we report 
data up to 90 days. The lower dose 
and fewer injections required to trig-
ger an immune response can be at 
least partially explained by using a 
whole virus vaccine and an aluminum 
phosphate adjuvant system. The use 
of a different adjuvant system than 
ours may have inﬂ  uenced the results 
of other trials (9,10). Other investiga-
tors used a modiﬁ  ed HI method with 
horse erythrocytes, which are known 
to be more sensitive for inﬂ  uenza A 
(H5N1) subtype than the convention-
ally used turkey or chicken erythro-
cytes (8,9). Thus, if horse erythro-
cytes had been used in our study, the 
vaccine would likely have been even 
more immunogenic.
This study found fewer, less fre-
quent, and milder side effects than 
did other trials of inﬂ  uenza A (H5N1) 
vaccines published so far (8–10). 
This could possibly be explained by 
the smaller dose used. Also, the en-
dotoxin content of 0.1 IU/mL in our 
vaccine was much smaller then the 
allowed amount of 100 IU/mL by 
standards (5).
We report an inactivated whole 
virus vaccine that is safe and immu-
nogenic in healthy adults and that re-
quires a low dose and only 1 injection 
to trigger an immune response. We are 
conducting trials in elderly persons 
and children.
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Resistance to 
Dihydroartemisinin
To the Editor: The title of the let-
ter by Cojean et al. (1) is misleading. 
The data presented essentially point to 
an absence of in vitro resistance to di-
hydroartemisinin (dhART) in the pan-
el of African isolates studied, with 1 of 
397 isolates having an elevated 50% 
inhibitory concentration (IC50) for 
dhART. The S769N PfATPase6 muta-
tion associated with in vitro resistance 
to artemether (2) was observed in 1 
isolate. This mutant isolate had a low 
IC50 for dhART, but its IC50 for arte-
mether has not been tested. Since the 
relationship between in vitro suscepti-
bility to artemether and dhART is still 
uncertain (3), these data do not dis-
prove the association of a PfATPase6 
S769N polymorphism with elevated 
IC50 for artemether that was observed 
in isolates from French Guiana (2).
Worth noting is that the associa-
tion of the S769N PfATPase6 poly-
morphism with elevated IC50 for arte-
mether was conﬁ   rmed in an isolate 
collected in French Guiana in 2005; 
that isolate had an IC50 for artemether 
of 127 nmol/L. Molecular typing iden-
tiﬁ  ed 2 clonal types, 1 with a wild-type 
PfATPase6 allele and 1 with a S769N 